Clinical Trial Update: Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction [Phase 3]

View source ↗

Summary

Phase 3 trial of oral treprostinil in pulmonary hypertension due to heart failure with preserved ejection fraction was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Pulmonary Hypertension

Drugs mentioned

• Treprostinil (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction | Phase 3 | Status: TERMINATED | Results posted: 2020-10-22